Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report) reached a new 52-week high on Tuesday . The stock traded as high as $66.90 and last traded at $65.00, with a volume of 255858 shares. The stock had previously closed at $66.18.
Gemini Therapeutics Stock Performance
The firm’s 50 day simple moving average is $58.16 and its 200-day simple moving average is $50.13. The company has a market capitalization of $2.75 billion, a price-to-earnings ratio of -63.50 and a beta of -0.12.
Gemini Therapeutics Company Profile
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Featured Stories
- Five stocks we like better than Gemini Therapeutics
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Micron Stock Under $100: Seize the AI-Driven Upside
- P/E Ratio Calculation: How to Assess Stocks
- AI’s Next Big Winners: 3 Small-Cap Stocks to Watch in 2025
- ETF Screener: Uses and Step-by-Step Guide
- SolarEdge Stock Climbs Back: Goldman Sachs Sees 40% Upside
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-usd-0005-logo-1200x675.jpg&h=45&w=95&zc=2){kind=logo}
